A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT03668119 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Pan Tumor

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb